EGFR and gastric cancer: Accordingly, overexpression of GPAA1 profoundly promoted the proliferation of gastric cancer cells, an effect that was counteracted by the administration of trastuzumab, a blocker simultaneously targeting EGFR and ERBB2 (Fig. 4h).